Journal of Southern Medical University ›› 2026, Vol. 46 ›› Issue (1): 83-93.doi: 10.12122/j.issn.1673-4254.2026.01.09
Previous Articles Next Articles
Zhaoyong LI1(
), Fenghua ZHOU1, Xiaomin SUN1,2, Huashan ZHAO1, Yao JIN1, Peikun HE1, Yuhua JIA1,2()
Received:2025-07-24
Online:2026-01-20
Published:2026-01-16
Contact:
Yuhua JIA
E-mail:1425519001@qq.com;jyh@smu.edu.cn
Supported by:Zhaoyong LI, Fenghua ZHOU, Xiaomin SUN, Huashan ZHAO, Yao JIN, Peikun HE, Yuhua JIA. Jiangzhi Quban Recipe improves type 2 diabetes mellitus complicated with hyperlipidemia by multi-target regulation of the inflammation-metabolism network: network pharmacology analysis and clinical validation[J]. Journal of Southern Medical University, 2026, 46(1): 83-93.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.j-smu.com/EN/10.12122/j.issn.1673-4254.2026.01.09
| Target gene | Forward primer (5' to 3') | Reverse primer (5' to 3') |
|---|---|---|
| β-actin | GGCTGTATTCCCCTCCATCG | CCAGTTGGTAACAATGCCATGT |
| IL-6 | TAGTCCTTCCTACCCCAATTTCC | TTGGTCCTTAGCCACTCCTTC |
| IL-1β | TTCAGGCAGGCAGTATCACTC | GAAGGTCCACGGGAAAGACAC |
| TNF-α | TGGAACTGGCAGAAGAGGCAC | AGGGTCTGGGCCATAGAACTGA |
Tab.1 Sequences of primers for RT-qPCR
| Target gene | Forward primer (5' to 3') | Reverse primer (5' to 3') |
|---|---|---|
| β-actin | GGCTGTATTCCCCTCCATCG | CCAGTTGGTAACAATGCCATGT |
| IL-6 | TAGTCCTTCCTACCCCAATTTCC | TTGGTCCTTAGCCACTCCTTC |
| IL-1β | TTCAGGCAGGCAGTATCACTC | GAAGGTCCACGGGAAAGACAC |
| TNF-α | TGGAACTGGCAGAAGAGGCAC | AGGGTCTGGGCCATAGAACTGA |
Fig.1 Venn diagram of common targets between the recipe and the disease.
Fig.2 Compound-Component-Active Ingredient-Target-Disease" network.
| MOL ID | Molecule name | TCM | OB (%) | DL | Degree |
|---|---|---|---|---|---|
| MOL000098 | Quercetin | Zhizi;Huanglian;Sanqi;Huzhang | 46.43 | 0.28 | 56 |
| MOL000422 | Kaempferol | Zhizi | 41.88 | 0.24 | 18 |
| MOL000006 | Luteolin | Danshen;Huzhang | 36.16 | 0.25 | 17 |
| MOL007154 | Tanshinone IIA | Danshen | 49.89 | 0.4 | 11 |
| MOL000449 | stigmasterol | Zhizi;Chishao;jmz;Sanqi | 43.83 | 0.76 | 11 |
| MOL000785 | palmatine | Huanglian | 64.6 | 0.65 | 10 |
| MOL007093 | dan-shexinkum d | Danshen | 38.88 | 0.55 | 10 |
| MOL000358 | beta-sitosterol | Zhizi;Chishao;Sanqi;Huzhang | 36.91 | 0.75 | 9 |
| MOL003095 | 5-hydroxy-7-methoxy-2-(3,4,5-trimethoxyphenyl) chromone | Zhizi | 51.96 | 0.41 | 9 |
| MOL002904 | Berlambine | Huanglian | 36.68 | 0.82 | 8 |
Tab.2 Effective active ingredients in Jiangzhi Quban Recipe
| MOL ID | Molecule name | TCM | OB (%) | DL | Degree |
|---|---|---|---|---|---|
| MOL000098 | Quercetin | Zhizi;Huanglian;Sanqi;Huzhang | 46.43 | 0.28 | 56 |
| MOL000422 | Kaempferol | Zhizi | 41.88 | 0.24 | 18 |
| MOL000006 | Luteolin | Danshen;Huzhang | 36.16 | 0.25 | 17 |
| MOL007154 | Tanshinone IIA | Danshen | 49.89 | 0.4 | 11 |
| MOL000449 | stigmasterol | Zhizi;Chishao;jmz;Sanqi | 43.83 | 0.76 | 11 |
| MOL000785 | palmatine | Huanglian | 64.6 | 0.65 | 10 |
| MOL007093 | dan-shexinkum d | Danshen | 38.88 | 0.55 | 10 |
| MOL000358 | beta-sitosterol | Zhizi;Chishao;Sanqi;Huzhang | 36.91 | 0.75 | 9 |
| MOL003095 | 5-hydroxy-7-methoxy-2-(3,4,5-trimethoxyphenyl) chromone | Zhizi | 51.96 | 0.41 | 9 |
| MOL002904 | Berlambine | Huanglian | 36.68 | 0.82 | 8 |
Fig.3 PPI network. A: STRING; B: Cytoscape.
Fig.4 Top 10 hub genes ranked by the MCC algorithm.
Fig.5 Results of GO functional enrichment analysis (A) and KEGG pathway enrichment analysis (B).
| Group | Body weight (g) | FBG (mmol/L) |
|---|---|---|
| Blank control | 32.57±1.00 | 5.02±0.47 |
| Model | 48.85±3.35## | 7.45±0.65## |
| JZQBR-L | 45.17±3.22* | 7.00±0.61 |
| JZQBR-H | 42.00±2.14** | 6.52±0.42* |
| Simvastatin | 43.85±1.65** | 6.92±0.47 |
Tab.3 Effects of Jiangzhi Quban Recipe on body weight and fasting blood glucose in high-fat diet mice (Mean±SD, n=6)
| Group | Body weight (g) | FBG (mmol/L) |
|---|---|---|
| Blank control | 32.57±1.00 | 5.02±0.47 |
| Model | 48.85±3.35## | 7.45±0.65## |
| JZQBR-L | 45.17±3.22* | 7.00±0.61 |
| JZQBR-H | 42.00±2.14** | 6.52±0.42* |
| Simvastatin | 43.85±1.65** | 6.92±0.47 |
| Group | TG (mmol/L) | TC (mmol/L) | LDL-C (mmol/L) | HDL-C (mmol/L) |
|---|---|---|---|---|
| Blank control | 0.48±0.13 | 3.12±0.82 | 0.26±0.07 | 1.49±0.15 |
| Model | 2.87±0.62## | 21.28±2.51## | 15.65±1.39## | 1.60±0.14 |
| JZQBR-L | 2.33±0.27* | 19.77±1.76 | 15.10±1.27 | 1.72±0.55 |
| JZQBR-H | 2.13±0.31** | 18.70±1.41* | 13.68±1.44* | 1.81±0.16 |
| Simvastatin | 1.96±0.24** | 17.07±1.40** | 13.51±1.24* | 1.92±0.22 |
Tab.4 Effects of Jiangzhi Quban Recipe on serum lipid profiles in high-fat diet mice (Mean±SD, n=6)
| Group | TG (mmol/L) | TC (mmol/L) | LDL-C (mmol/L) | HDL-C (mmol/L) |
|---|---|---|---|---|
| Blank control | 0.48±0.13 | 3.12±0.82 | 0.26±0.07 | 1.49±0.15 |
| Model | 2.87±0.62## | 21.28±2.51## | 15.65±1.39## | 1.60±0.14 |
| JZQBR-L | 2.33±0.27* | 19.77±1.76 | 15.10±1.27 | 1.72±0.55 |
| JZQBR-H | 2.13±0.31** | 18.70±1.41* | 13.68±1.44* | 1.81±0.16 |
| Simvastatin | 1.96±0.24** | 17.07±1.40** | 13.51±1.24* | 1.92±0.22 |
Fig.6 Effects of Jiangzhi Quban Recipe on hepatic pathological morphology and lipid deposition in high-fat diet mice (Scale bar=100 µm).
| Group | IL-6 | IL-1β | TNF-α |
|---|---|---|---|
| Blank control | 1.00±0.28 | 1.00±0.45 | 1.00±0.37 |
| Model | 14.06±3.32## | 7.44±1.39## | 7.59±1.29## |
| JZQBR-L | 12.41±3.12 | 6.60±0.80 | 6.21±0.77* |
| JZQBR-H | 9.87±2.74* | 5.59±0.91* | 4.73±0.74** |
| Simvastatin | 13.14±2.39 | 6.23±1.20 | 6.61±1.05 |
Tab.5 Effects of Jiangzhi Quban Recipe on hepatic inflammatory factor transcription levels in high-fat diet mice (Mean±SD, n=6)
| Group | IL-6 | IL-1β | TNF-α |
|---|---|---|---|
| Blank control | 1.00±0.28 | 1.00±0.45 | 1.00±0.37 |
| Model | 14.06±3.32## | 7.44±1.39## | 7.59±1.29## |
| JZQBR-L | 12.41±3.12 | 6.60±0.80 | 6.21±0.77* |
| JZQBR-H | 9.87±2.74* | 5.59±0.91* | 4.73±0.74** |
| Simvastatin | 13.14±2.39 | 6.23±1.20 | 6.61±1.05 |
| Parameter | Observation group | Positive control group | P |
|---|---|---|---|
| Body weight (kg) | 70.52±13.39 | 66.88±12.99 | 0.31 |
| BMI (kg/m²) | 25.40±3.47 | 24.73±4.11 | 0.55 |
| TG (mmol/L) | 3.48±3.47 | 2.45±1.21 | 0.10 |
| TC (mmol/L) | 5.16±1.07 | 5.72±1.08 | 0.06 |
| HDL-C (mmol/L) | 1.08±0.26 | 1.07±0.22 | 0.85 |
| LDL-C (mmol/L) | 3.05±0.94 | 3.63±0.89 | 0.61 |
| FBG (mmol/L) | 8.79±2.37 | 9.13±3.36 | 0.62 |
| HbA1c (%) | 7.85±1.73 | 8.92±2.72 | 0.08 |
Tab.6 Comparison of body weight, blood lipid and blood glucose levels of the patients between the two groups before treatment (Mean±SD, n=36)
| Parameter | Observation group | Positive control group | P |
|---|---|---|---|
| Body weight (kg) | 70.52±13.39 | 66.88±12.99 | 0.31 |
| BMI (kg/m²) | 25.40±3.47 | 24.73±4.11 | 0.55 |
| TG (mmol/L) | 3.48±3.47 | 2.45±1.21 | 0.10 |
| TC (mmol/L) | 5.16±1.07 | 5.72±1.08 | 0.06 |
| HDL-C (mmol/L) | 1.08±0.26 | 1.07±0.22 | 0.85 |
| LDL-C (mmol/L) | 3.05±0.94 | 3.63±0.89 | 0.61 |
| FBG (mmol/L) | 8.79±2.37 | 9.13±3.36 | 0.62 |
| HbA1c (%) | 7.85±1.73 | 8.92±2.72 | 0.08 |
| Parameter | Observation group | Positive control group | P |
|---|---|---|---|
| AST (U/L) | 24.08±12.16 | 23.84±14.10 | 0.92 |
| ALT (U/L) | 31.28±20.46 | 27.79±15.84 | 0.46 |
| SCr (μmol/L) | 72.35±16.32 | 68.78±19.89 | 0.47 |
| Urea (mmol/L) | 5.23±1.66 | 5.36±1.57 | 0.56 |
| ALBU (mg/L) | 28.70±36.58 | 44.89±56.07 | 0.22 |
Tab.7 Comparison of liver and kidney function levels of the patients between the two groups before treatment (Mean±SD, n=36)
| Parameter | Observation group | Positive control group | P |
|---|---|---|---|
| AST (U/L) | 24.08±12.16 | 23.84±14.10 | 0.92 |
| ALT (U/L) | 31.28±20.46 | 27.79±15.84 | 0.46 |
| SCr (μmol/L) | 72.35±16.32 | 68.78±19.89 | 0.47 |
| Urea (mmol/L) | 5.23±1.66 | 5.36±1.57 | 0.56 |
| ALBU (mg/L) | 28.70±36.58 | 44.89±56.07 | 0.22 |
| Parameter | Observation group | Positive control group | ||
|---|---|---|---|---|
| Before treatment | After 12 weeks treatment | Before treatment | After 12 weeks treatment | |
| Body weight (kg) | 72.24±12.99 | 69.58±13.06△△ | 66.86±13.21 | 65.68±12.97* |
| BMI (kg/m²) | 25.99±3.18 | 25.29±3.49△△ | 24.73±4.11 | 24.23±3.47* |
| TG (mmol/L) | 3.84±3.77 | 2.78±2.18△ | 2.53±1.25 | 2.03±1.11** |
| TC (mmol/L) | 5.18±1.11 | 4.95±1.14 | 5.75±1.03 | 4.41±1.02** |
| HDL-C (mmol/L) | 1.08±0.27 | 1.14±0.26 | 1.05±0.23 | 1.17±0.31* |
| LDL-C (mmol/L) | 2.99±0.95 | 2.87±0.92 | 3.61±0.81 | 2.55±0.79** |
| FBG (mmol/L) | 8.91±2.52 | 6.92±2.02△△ | 9.09±3.46 | 7.92±2.33 |
| HbA1c (%) | 7.70±1.46 | 6.51±0.94△△ | 8.87±2.89 | 6.75±1.12** |
Tab.8 Comparison of body weight, blood lipid, and blood glucose levels of the patients before and after 12 weeks of treatment (Mean±SD, n=36)
| Parameter | Observation group | Positive control group | ||
|---|---|---|---|---|
| Before treatment | After 12 weeks treatment | Before treatment | After 12 weeks treatment | |
| Body weight (kg) | 72.24±12.99 | 69.58±13.06△△ | 66.86±13.21 | 65.68±12.97* |
| BMI (kg/m²) | 25.99±3.18 | 25.29±3.49△△ | 24.73±4.11 | 24.23±3.47* |
| TG (mmol/L) | 3.84±3.77 | 2.78±2.18△ | 2.53±1.25 | 2.03±1.11** |
| TC (mmol/L) | 5.18±1.11 | 4.95±1.14 | 5.75±1.03 | 4.41±1.02** |
| HDL-C (mmol/L) | 1.08±0.27 | 1.14±0.26 | 1.05±0.23 | 1.17±0.31* |
| LDL-C (mmol/L) | 2.99±0.95 | 2.87±0.92 | 3.61±0.81 | 2.55±0.79** |
| FBG (mmol/L) | 8.91±2.52 | 6.92±2.02△△ | 9.09±3.46 | 7.92±2.33 |
| HbA1c (%) | 7.70±1.46 | 6.51±0.94△△ | 8.87±2.89 | 6.75±1.12** |
| Parameter | Observation group | Positive control group | ||
|---|---|---|---|---|
| Before treatment | After 12 weeks treatment | Before treatment | After 12 weeks treatment | |
| AST (U/L) | 26.23±12.56 | 19.43±6.21△△ | 24.25±14.94 | 20.09±7.81 |
| ALT (U/L) | 34.84±21.25 | 22.04±10.28△△ | 27.84±16.19 | 21.66±10.91 |
| SCr (μmol/L) | 76.10±15.83 | 75.21±17.73 | 68.49±20.08 | 68.02±19.04 |
| Urea (mmol/L) | 5.34±1.80 | 5.96±1.65 | 5.42±1.47 | 5.85±1.46 |
| ALBU (mg/L) | 33.55±40.87 | 35.19±49.16 | 47.29±59.81 | 76.26±189.12 |
Tab.9 Comparison of liver and kidney function indicators of the patients before and after 12 weeks of treatment (Mean±SD, n=36)
| Parameter | Observation group | Positive control group | ||
|---|---|---|---|---|
| Before treatment | After 12 weeks treatment | Before treatment | After 12 weeks treatment | |
| AST (U/L) | 26.23±12.56 | 19.43±6.21△△ | 24.25±14.94 | 20.09±7.81 |
| ALT (U/L) | 34.84±21.25 | 22.04±10.28△△ | 27.84±16.19 | 21.66±10.91 |
| SCr (μmol/L) | 76.10±15.83 | 75.21±17.73 | 68.49±20.08 | 68.02±19.04 |
| Urea (mmol/L) | 5.34±1.80 | 5.96±1.65 | 5.42±1.47 | 5.85±1.46 |
| ALBU (mg/L) | 33.55±40.87 | 35.19±49.16 | 47.29±59.81 | 76.26±189.12 |
| Parameter | Observation group | Positive control group | P |
|---|---|---|---|
| Body weight (kg) | 69.58±13.06 | 65.68±12.97 | 0.25 |
| BMI (kg/m²) | 25.29±3.49 | 24.23±3.47 | 0.24 |
| TG (mmol/L) | 4.95±1.14 | 4.41±1.02 | 0.06 |
| TC (mmol/L) | 2.78±2.18 | 2.03±1.11 | 0.10 |
| HDL-C (mmol/L) | 1.14±0.26 | 1.17±0.31 | 0.73 |
| LDL-C (mmol/L) | 2.87±0.92 | 2.55±0.79 | 0.16 |
| FBG (mmol/L) | 6.92±2.02 | 7.95±2.29 | 0.04 |
| HbA1c (%) | 6.51±0.94 | 6.75±1.12 | 0.29 |
Tab.10 Comparison of body weight, blood lipid, and blood glucose levels of the patients between two groups after 12 weeks of treatment (Mean±SD, n=36)
| Parameter | Observation group | Positive control group | P |
|---|---|---|---|
| Body weight (kg) | 69.58±13.06 | 65.68±12.97 | 0.25 |
| BMI (kg/m²) | 25.29±3.49 | 24.23±3.47 | 0.24 |
| TG (mmol/L) | 4.95±1.14 | 4.41±1.02 | 0.06 |
| TC (mmol/L) | 2.78±2.18 | 2.03±1.11 | 0.10 |
| HDL-C (mmol/L) | 1.14±0.26 | 1.17±0.31 | 0.73 |
| LDL-C (mmol/L) | 2.87±0.92 | 2.55±0.79 | 0.16 |
| FBG (mmol/L) | 6.92±2.02 | 7.95±2.29 | 0.04 |
| HbA1c (%) | 6.51±0.94 | 6.75±1.12 | 0.29 |
| Parameter | Observation group | Positive control group | P |
|---|---|---|---|
| AST (U/L) | 19.26±6.17 | 20.09±7.81 | 0.65 |
| ALT (U/L) | 21.64±10.32 | 21.66±10.91 | 0.99 |
| SCr (μmol/L) | 74.57±17.36 | 68.02±19.04 | 0.17 |
| Urea (mmol/L) | 5.93±1.62 | 5.85±1.46 | 0.83 |
| ALBU (mg/L) | 35.15±49.30 | 71.59±182.80 | 0.32 |
Tab.11 Comparison of liver and kidney function levels between two groups after 12 weeks of treatment (Mean±SD, n=36)
| Parameter | Observation group | Positive control group | P |
|---|---|---|---|
| AST (U/L) | 19.26±6.17 | 20.09±7.81 | 0.65 |
| ALT (U/L) | 21.64±10.32 | 21.66±10.91 | 0.99 |
| SCr (μmol/L) | 74.57±17.36 | 68.02±19.04 | 0.17 |
| Urea (mmol/L) | 5.93±1.62 | 5.85±1.46 | 0.83 |
| ALBU (mg/L) | 35.15±49.30 | 71.59±182.80 | 0.32 |
| Group | Total case | Markedly effective | Effective case | Ineffective case | Total effective rate | P |
|---|---|---|---|---|---|---|
| Observation | 29 | 11 | 11 | 7 | 75.86% | >0.05 |
| Positive control | 31 | 22 | 2 | 7 | 77.42% |
Tab.12 Comparison of treatment efficacy between two groups after 12 weeks of treatment (n)
| Group | Total case | Markedly effective | Effective case | Ineffective case | Total effective rate | P |
|---|---|---|---|---|---|---|
| Observation | 29 | 11 | 11 | 7 | 75.86% | >0.05 |
| Positive control | 31 | 22 | 2 | 7 | 77.42% |
| [1] | Ji Q, Chai S, Zhang R, et al. Prevalence and co-prevalence of comorbidities among Chinese adult patients with type 2 diabetes mellitus: a cross-sectional, multicenter, retrospective, observational study based on 3B study database[J]. Front Endocrinol: Lausanne, 2024, 15: 1362433. doi：10.3389/fendo.2024.1362433 |
| [2] | Fan D, Li L, Li Z, et al. Effect of hyperlipidemia on the incidence of cardio-cerebrovascular events in patients with type 2 diabetes[J]. Lipids Health Dis, 2018, 17(1): 102. doi：10.1186/s12944-018-0676-x |
| [3] | Li J, Shi L, Zhao G, et al. High triglyceride levels increase the risk of diabetic microvascular complications: a cross-sectional study[J]. Lipids Health Dis, 2023, 22(1): 109. doi：10.1186/s12944-023-01873-5 |
| [4] | 中华医学会糖尿病学分会. 中国2型糖尿病防治指南（2020年版）[J]. 中华糖尿病杂志, 2021, 13(4): 315-409. |
| [5] | Bjornstad P, Eckel RH. Pathogenesis of lipid disorders in insulin resistance: a brief review[J]. Curr Diabetes Rep, 2018, 18(12): 127. doi：10.1007/s11892-018-1101-6 |
| [6] | Elkanawati RY, Sumiwi SA, Levita J. Impact of lipids on insulin resistance: insights from human and animal studies[J]. Drug Des Devel Ther, 2024, 18: 3337-60. doi：10.2147/dddt.s468147 |
| [7] | Galantini MPL, Ribeiro IS, Gonçalves CV, et al. The sweet fuel of inflammation: new perspectives on the complex web that interconnects diabetes[J]. Exp Gerontol, 2022, 167: 111905. doi：10.1016/j.exger.2022.111905 |
| [8] | Xiong PJ, Zhang F, Liu F, et al. Metaflammation in glucolipid metabolic disorders: Pathogenesis and treatment[J]. Biomed Pharmacother, 2023, 161: 114545. doi：10.1016/j.biopha.2023.114545 |
| [9] | 李琦文. HMG-CoA还原酶抑制剂-他汀类药物的作用及机制[J]. 中国现代药物应用, 2014, 8(17): 228-9. |
| [10] | 周凤华, 金 瑶, 刁慧玲, 等. 贾钰华教授论治冠心病临证经验精粹[J]. 湖南中医药大学学报, 2025, 45(9): 1786-93. |
| [11] | Zhai Y, Liu L, Zhang F, et al. Network pharmacology: a crucial approach in traditional Chinese medicine research[J]. Chin Med, 2025, 20(1): 8-15. doi：10.1186/s13020-024-01056-z |
| [12] | 王澄槟, 胡浩彬, 徐芷晴, 等. 基于网络药理学和分子对接探讨桃红四物汤治疗动脉粥样硬化的作用机制[J]. 中西医结合心脑血管病杂志, 2025(18): 2760-9. |
| [13] | Bu Y, Li Z, Wang C, et al. Anemoside B4 targets RAGE to attenuate ferroptosis in sepsis-induced acute lung injury[J]. Front Pharmacol, 2025, 16: 1590797. doi：10.3389/fphar.2025.1590797 |
| [14] | 李 楠, 陈 蕾, 张 琨. 基于网络药理学探讨人参调控铁死亡抗阿尔茨海默病的潜在作用机制[J]. 现代药物与临床, 2022, 37(2): 244-51. |
| [15] | 中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2017年版)[J]. 中国实用内科杂志, 2018, 38(4): 292-344. |
| [16] | 诸骏仁, 高润霖, 赵水平, 等. 中国成人血脂异常防治指南(2016年修订版)[J]. 中国循环杂志, 2016, 31(10): 937-53. |
| [17] | Huang X, Fang J, Lai W, et al. IL-6/STAT3 axis activates Glut5 to regulate fructose metabolism and tumorigenesis[J]. Int J Biol Sci, 2022, 18(9): 3668-75. doi：10.7150/ijbs.68990 |
| [18] | Vida M, Gavito AL, Pavón FJ, et al. Chronic administration of recombinant IL-6 upregulates lipogenic enzyme expression and aggravates high-fat-diet-induced steatosis in IL-6-deficient mice[J]. Dis Model Mech, 2015, 8(7): 721-31. |
| [19] | Herder C, Dalmas E, Böni-Schnetzler M, et al. The IL-1 pathway in type 2 diabetes and cardiovascular complications[J]. Trends Endocrinol Metab, 2015, 26(10): 551-63. doi：10.1016/j.tem.2015.08.001 |
| [20] | Meier DT, de Paula Souza J, Donath MY. Targeting the NLRP3 inflammasome-IL-1β pathway in type 2 diabetes and obesity[J]. Diabetologia, 2025, 68(1): 3-16. doi：10.1007/s00125-024-06306-1 |
| [21] | Cawthorn WP, Sethi JK. TNF‐α and adipocyte biology[J]. FEBS Letters, 2008, 582(1): 117-31. doi：10.1016/j.febslet.2007.11.051 |
| [22] | Park JE, Han JS. Improving the effect of ferulic acid on inflammation and insulin resistance by regulating the JNK/ERK and NF-κB pathways in TNF‑α‑treated 3T3-L1 adipocytes[J]. Nutrients, 2024, 16(2): 294. doi：10.3390/nu16020294 |
| [23] | Dhanya R, Arya AD, Nisha P, et al. Quercetin, a lead compound against type 2 diabetes ameliorates glucose uptake via AMPK pathway in skeletal muscle cell line[J]. Front Pharmacol, 2017, 8: 336. doi：10.3389/fphar.2017.00336 |
| [24] | Salehi B, Machin L, Monzote L, et al. Therapeutic potential of quercetin: new insights and perspectives for human health[J]. ACS Omega, 2020, 5(20): 11849-72. doi：10.1021/acsomega.0c01818 |
| [25] | Kadioglu O, Nass J, Saeed ME, et al. Kaempferol is an anti-inflammatory compound with activity towards NF‑κB pathway proteins[J]. Anticancer Res, 2015, 35(5): 2645-50. |
| [26] | Lee B, Kwon M, Choi JS, et al. Kaempferol isolated fromNelumbo nuciferaInhibits lipid accumulation and increases fatty acid oxidation signaling in adipocytes[J]. J Med Food, 2015, 18(12): 1363-70. doi：10.1089/jmf.2015.3457 |
| [27] | Kwon EY, Choi MS. Luteolin targets the toll-like receptor signaling pathway in prevention of hepatic and adipocyte fibrosis and insulin resistance in diet-induced obese mice[J]. Nutrients, 2018, 10(10): E1415. doi：10.3390/nu10101415 |
| [28] | Zhang L, Han YJ, Zhang X, et al. Luteolin reduces obesity-associated insulin resistance in mice by activating AMPKα1 signalling in adipose tissue macrophages[J]. Diabetologia, 2016, 59(10): 2219-28. doi：10.1007/s00125-016-4039-8 |
| [29] | Kwon EY, Jung UJ, Park T, et al. Luteolin attenuates hepatic steatosis and insulin resistance through the interplay between the liver and adipose tissue in mice with diet-induced obesity[J]. Diabetes, 2015, 64(5): 1658-69. doi：10.2337/db14-0631 |
| [30] | Kosmalski M, Ziółkowska S, Czarny P, et al. The coexistence of nonalcoholic fatty liver disease and type 2 diabetes mellitus[J]. J Clin Med, 2022, 11(5): 1375. doi：10.3390/jcm11051375 |
| [1] | Qin HU, Hua JIN. Qingshen Granules improves renal function of patients with chronic kidney disease damp-heat syndrome by activating the miR-23b and Nrf2 pathway [J]. Journal of Southern Medical University, 2025, 45(9): 1867-1879. |
| [2] | Ziwei YANG, Chang LÜ, Zhu DONG, Shulei JI, Shenghui BI, Xuehua ZHANG, Xiaowu WANG. Rosa laevigata Michx. inhibits pulmonary arterial smooth muscle cell proliferation in hypertension by modulating the Src-AKT1 axis [J]. Journal of Southern Medical University, 2025, 45(9): 1889-1902. |
| [3] | Qi YUN, Ruoli DU, Yuying HE, Yixin ZHANG, Jiahui WANG, Hongwei YE, Zhenghong LI, Qin GAO. Cinnamic acid ameliorates doxorubicin-induced myocardial injury in mice by attenuating cardiomyocyte ferroptosis via inhibiting TLR4 [J]. Journal of Southern Medical University, 2025, 45(9): 1946-1958. |
| [4] | Lu RAO, Jiahe DING, Jiangping WEI, Yong YANG, Xiaomei ZHANG, Jirui WANG. Flos Sophorae improves psoriasis in mice by inhibiting the PI3K/AKT pathway [J]. Journal of Southern Medical University, 2025, 45(9): 1989-1996. |
| [5] | Chuyu DENG, Xueying WANG, Lixiang GAN, Dayu WANG, Xiaoyan ZHENG, Chunzhi TANG. Electroacupuncture at Zusanli improves blood lipid disorders in hyperlipidemic mice by improving gut microbiota structure [J]. Journal of Southern Medical University, 2025, 45(8): 1633-1642. |
| [6] | Xinyuan CHEN, Chengting WU, Ruidi LI, Xueqin PAN, Yaodan ZHANG, Junyu TAO, Caizhi LIN. Shuangshu Decoction inhibits growth of gastric cancer cell xenografts by promoting cell ferroptosis via the P53/SLC7A11/GPX4 axis [J]. Journal of Southern Medical University, 2025, 45(7): 1363-1371. |
| [7] | Liming WANG, Hongrui CHEN, Yan DU, Peng ZHAO, Yujie WANG, Yange TIAN, Xinguang LIU, Jiansheng LI. Yiqi Zishen Formula ameliorates inflammation in mice with chronic obstructive pulmonary disease by inhibiting the PI3K/Akt/NF-κB signaling pathway [J]. Journal of Southern Medical University, 2025, 45(7): 1409-1422. |
| [8] | Yinfu ZHU, Yiran LI, Yi WANG, Yinger HUANG, Kunxiang GONG, Wenbo HAO, Lingling SUN. Therapeutic mechanism of hederagenin, an active component in Guizhi Fuling Pellets, against cervical cancer in nude mice [J]. Journal of Southern Medical University, 2025, 45(7): 1423-1433. |
| [9] | Ruimin HAN, Manke ZHAO, Junfang YUAN, Zhenhong SHI, Zhen WANG, Defeng WANG. Live combined Bacillus subtilis and Enterococcus faecium improves glucose and lipid metabolism in type 2 diabetic mice with circadian rhythm disruption via the SCFAs/GPR43/GLP-1 pathway [J]. Journal of Southern Medical University, 2025, 45(7): 1490-1497. |
| [10] | Lijun HE, Xiaofei CHEN, Chenxin YAN, Lin SHI. Inhibitory effect of Fuzheng Huaji Decoction against non-small cell lung cancer cells in vitro and the possible molecular mechanism [J]. Journal of Southern Medical University, 2025, 45(6): 1143-1152. |
| [11] | Guoyong LI, Renling LI, Yiting LIU, Hongxia KE, Jing LI, Xinhua WANG. Therapeutic mechanism of Arctium lappa extract for post-viral pneumonia pulmonary fibrosis: a metabolomics, network pharmacology analysis and experimental verification [J]. Journal of Southern Medical University, 2025, 45(6): 1185-1199. |
| [12] | Liping GUAN, Yan YAN, Xinyi LU, Zhifeng LI, Hui GAO, Dong CAO, Chenxi HOU, Jingyu ZENG, Xinyi LI, Yang ZHAO, Junjie WANG, Huilong FANG. Compound Centella asiatica formula alleviates Schistosoma japonicum-induced liver fibrosis in mice by inhibiting the inflammation-fibrosis cascade via regulating the TLR4/MyD88 pathway [J]. Journal of Southern Medical University, 2025, 45(6): 1307-1316. |
| [13] | Peipei TANG, Yong TAN, Yanyun YIN, Xiaowei NIE, Jingyu HUANG, Wenting ZUO, Yuling LI. Tiaozhou Ziyin recipe for treatment of premature ovarian insufficiency: efficacy, safety and mechanism [J]. Journal of Southern Medical University, 2025, 45(5): 929-941. |
| [14] | Xiaotao LIANG, Yifan XIONG, Xueqi LIU, Xiaoshan LIANG, Xiaoyu ZHU, Wei XIE. Huoxue Shufeng Granule alleviates central sensitization in chronic migraine mice via TLR4/NF-κB inflammatory pathway [J]. Journal of Southern Medical University, 2025, 45(5): 986-994. |
| [15] | Niandong RAN, Jie LIU, Jian XU, Yongping ZHANG, Jiangtao GUO. n-butanol fraction of ethanol extract of Periploca forrestii Schltr.: its active components, targets and pathways for treating Alcheimer's disease in rats [J]. Journal of Southern Medical University, 2025, 45(4): 785-798. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
